Drug Trial Radar · NCT01424670
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Last checked: Nov 19, 2026Latest source record: May 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
511
Actual
Start
Sep 2, 2011
Primary completion
Jul 4, 2016
Study completion Jul 4, 2016
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Aug 29, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to determine whether delamanid is effective in the treatment of multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during 6 months of treatment.
Conditions
- Multidrug-resistant Tuberculosis
Interventions
Delamanid + OBRDrug
The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
Placebo + OBRDrug
Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) SystemTime frame: Month 6
Locations
17 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Tartu, Estonia
Site not named
Riga, Latvia
Site not named
Šiauliai, Lithuania
Site not named
Vilnius, Lithuania
Site not named
Chisinau, Moldova
Site not named
Vorniceni, Moldova
Site not named
Alfonso Ugarte, Peru
Site not named
Comas, Peru
Site not named
El Agustino, Peru
Site not named
Lima Cercado, Peru
Site not named
Makati City, Philippines
Site not named
Quezon City, Philippines
Site not named
Dasmariñas, Cavite, Philippines
Site not named
Quezon City, National Capital Region, Philippines
Site not named
Cape Town, South Africa
Site not named
Durban, South Africa
Site not named
Klerksdorp, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.